Most patients with ER-positive HER2-negative advanced breast cancer commence on endocrine treatment combined with targeted therapy; reserving chemotherapy for patients with rapidly progressive disease or severe organ dysfunction. The gene discussed is ESR1; the disease is breast carcinoma.